HLD-0915 Earns FDA Fast Track Designation in Metastatic CRPC
Written by
Cancer Network
Published
0
comments
0
min
Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.